Advanced search
Publication Cover
Emerging Drugs Volume 6, 2001 - Issue 1
Journal homepage
20
Views
6
CrossRef citations to date
0
Altmetric
Review

Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria

Glenn W Kaatz B4333 John D Dingell VA Medical Center, 4646 John R, Detroit, MI48201, USA. [email protected]
&
Michael J Rybak The Anti-Infective Research Laboratory, Department of Pharmacy Services, Detroit Receiving Hospital and University Health CenterCollege of Pharmacy and Allied Health Professions and School of Medicine, Wayne State University, Detroit, MI 48201, USA
Pages 43-55 | Published online: 24 Feb 2005

Bibliography

  • HOLMBERG SD, SOLOMON SL, BLAKE PA: Health andeconomic impacts of antimicrobial resistance. Rev. Infect. Dis. (1987) 9:1065–1078.
  • BONTEN MJ, HAYDEN MK, NATHAN C, et al: Epidemi-ology of colonisation of patients and environment with vancomycin-resistant enterococci. Lancet (1996) 348:1615–1619.
  • MARTONE WJ: Spread of vancomycin-resistant entero-cocci: why did it happen in the United States Infect. Control Hosp. Epidemiol. (1998) 19:539–545.
  • RUBIN RJ, HARRINGTON CA, POON A, DIETRICH K, GREENE JA, MOIDUDDIN A: The economic impact of Staphylococcus aureus infections in New York City hospitals. Emerg. Infect. Dis. (1999) 5:9–17.
  • •A review of the costs associated with community- and nosocomially-acquired methicillin-susceptible and -resistant S. aureus infections.
  • WEINGARTEN CM, RYBAK MJ, JAHNS BE, STEVENSON JG, BROWN WJ, LEVINE DP: Resistant Acinetobacter baumannii infection and colonization and antimicro-bial treatment patterns in an urban teaching hospital. Pharmacother. (1999) 19:1080–1085.
  • PALADINO JA: Economic justification of antimicrobial management programs: implications of antimicrobial resistance. Am. J. Health Syst. Pharm. (2000) 57 (Suppl. 2):S10–S12.
  • JONES RN: Impact of changing pathogens and antimi-crobial susceptibility patterns in the treatment of serious infections in hospitalised patients. Am. J. Med. (1996) 1 0 0:3S–12S.
  • PFALLER MA, JONES RN, DOERN GV, KUGLER K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicro-bial susceptibility patterns from the SENTRY antimi-crobial surveillance program (United States and Canada, 1997). Antimicrob. Agents Chemother. (1998) 42:1762–1770.
  • EDMOND MB, WALLACE SE, MCCLISH DK, PFALLER MA, JONES RN, WENZEL RP: Nosocomial bloodstream infections in United States hospitals: a three-year analysis. an. Infect. Dis. (1999) 29:239–244.
  • ••A comprehensive surveillance study presenting incidenceand crude mortality data associated with organisms causing bloodstream infections.
  • SAHM DF, MARSILIO MK, PIAZZA G: Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database -USA. Clin. Infect. Dis. (1999) 29:259–263.
  • LIVERMORE DM: Antibiotic resistance in staphylococci. Int. J. Antimicrob. Agents (2000) 16 (Suppl.
  • SPINK WW, FERRIS V: Quantitative action of penicillin inhibitor from penicillin-resistant strains of staphylo-cocci. Science (1945) 102:221.
  • Mandell GL, Bennett JE, Dolin R (Eds.), Churchill Livingstone, Philadel-phia, USA (2000):2069–2092.
  • JEVONS MP: Celbenin-resistant staphylococci. Br. Med. J. (1961) 1:124–125.
  • FILE TM: Overview of resistance in the 1990s. Chest (1999) 115 (Suppl. 3):35–85.
  • FRIDKIN SK, EDWARDS JR, PICHETTE SC, et al.: Determi-nants of vancomycin use in adult intensive care units in 41 United States hospitals. Clin. Infect. Dis. (1999) 2 8:1119–1125.
  • LECLERCQ R, DERLOT E, DUVAL J, COURVALIN P: Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl. J. Med. (1988) 319:157–161.
  • HIRAMATSU K, HANAKI H, YABUTA K, OGURI T, TENOVER FC: Methicillin -resistantStaphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. (1997) 40:135–136.
  • PLOY MC, GRELAUD C, MARTIN C, DE LUMLEY L, DENIS F:First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet (1998) 351:1212.
  • •Describes the isolation of the first clinical GISA strain worldwide.
  • ANTONY SJ: Multidrug-resistant enterococci: the dawnof a new era in resistant pathogens. J Nail Med. Assoc. (1998) 90:537–540.
  • SCHOUTEN MA, HOOGKAMP-KORSTANJE JA, MEIS JF, VOSS A: Prevalence of vancomycin-resistant entero-cocci in Europe. European VRE study group. Eur. Microbiol. Infect. Dis. (2000) 19:816–822.
  • STROUD L, EDWARDS J, DANZING L, CULVER D, GAYNESR: Risk factors for mortality associated with entero-coccal bloodstream infections. Infect. Control Hosp. Epidemiol. (1996) 17:576–580.
  • LINDEN PK, PASCULLE AW, MANEZ, R et al: Differencesin outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin. Infect. Dis. (1996) 22:663–670.
  • •A study examining overall morbidity and mortality as they relate to vancomycin resistance in patients with E. faecium bloodstream infections.
  • PAPANICOLAOU GA, MEYERS BR, MEYERS J, et al.: Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin. Infect. Dis. (1996) 23:760–766.
  • MAINOUS MR, LIPSETT PA, O'BRIEN M: Enterococcal bacteremia in a surgical intensive care unit: does vancomycin resistance affect mortality The Johns Hopkins SICU Study Group. Arch. Surg. (1997) 132:76–81.
  • Mandell GL, Bennett JE, Dolin R (Eds.), Churchill Livingstone, Philadel-phia, USA (20003079–3090.
  • EDMOND MB, WENZEL RP, PASCULLE AW: Van comycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann. Intern. Med. (1996) 124:329–334.
  • HIRAMATSU K: The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am. J. Med. (1998) 1 04 (Suppl. 5A):7S–10S.
  • JOHNSON AP: Intermediate vancomycin resistance inStaphylococcus aureus: a major threat or a minor inconvenience J. Antimicrob. Chemother. (1998) 42:289–291.
  • MCMANUS J: Vancomycin resistant staphylococcus reported in Hong Kong. Br. Med. J. (1999) 318:626.
  • ROTUN SS, MCMATH V, SCHOONMAKER DJ, et al.: Staphy-lococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg. Infect. Dis. (1999) 5:147–149.
  • SMITH TL, PEARSON ML, WILCOX KR, et al.: Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-intermediate Staphylococcus aureus working group. N Engl. J. Med. (1999) 340:493–501.
  • RYBAK MJ, AKINS RL: Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options. Drugs (2001) 61:1–7.
  • ••A thorough review of the emergence of glycopeptideresistance in S. aureus and options for treatment of infections caused by such organisms.
  • SCHWALBE RS, STAPLETON JT, GILLIGAN PH: Emergence of vancomycin resistance in coag-ulase-negative staphylococci. N. EngI J. Med. (1987) 316:927–931.
  • RAAD I, ALRAHWAN A, ROLSTON K: Staphylococcus epidermidis: emerging resistance and need for alternative agents. Clin. Infect. Dis. (1998) 26:1182–1187.
  • SIERADZKIK VILLARI P, TOMASZ A: Decreased suscepti-bilities to teicoplanin and vancomycin among coagulase-negative methicillin -resistant clinical isolates of staphylococci. Antimicrob. Agents. Chemother. (1998) 42:100–107.
  • FRIDKIN SK: Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin. Infect. Dis. (2001) 32:108–115.
  • KISLAK JW, RAZAVI LM, DALY AK, FINLAND M: Suscepti-bility of pneumococci to nine antibiotics. Am. J. Med. Sci. (1965) 250:261–268.
  • CENTERS FOR DISEASE CONTROL AND PREVENTION: Defining the public health impact of drug-resistant Streptococcus pneumoniae: report of a working group. Mor. Mortal. Wkly. Rep. (1999) 45:RR–1.
  • DIEKEMA DJ, BRUEGGEMANN AB, DOERN GV: Antimicrobial-drug use and changes in resistance in Streptococcus pneumoniae. Emerg. Infect. Dis. (2000) 6:552–556.
  • THORNSBERRY C, JONES ME, HICKEY ML, MAURIZ Y, KAHN J, SAHM DF: Resistance surveillance of Strepto-coccus pneumoniae, Haemophilus influenzae and Moraxella cararrhalis isolated in the United States, 1997-1998.j Antimicrob. Chemother. (1999) 44:749–759.
  • SAHM DF, JONES ME, HICKEY ML, DIAKUN DR, MANI SV,THORNSBERRY C: Resistance surveillance of Strepto-coccus pneumoniae, Haemophilus influenzae and Moraxella cararrhalis isolated in Asia and Europe,1997-1998.j Antimicrob. Chemother. (2000) 45:457–466.
  • NOVAK R, HENRIQUES B, CHARPENTIER E, NORMARK S,TUOMANEN E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature (1999) 399:590–593.
  • MCCULLERS JA, ENGLISH BK, NOVAK R: Isolation andcharacterization of vancomycin-tolerant Strepto-coccus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J. Infect. Dis. (2000) 181:369–373.
  • WALLACE MR, MASCOLA JR, OLDFIELD C: Red man syndrome: incidence, etiology and prophylaxis. J. Infect. Dis. (1991) 164:1180–1185.
  • RYBAK MJ, BAILEY EM, WARBASSE LH: Absence of 'redman syndrome' in patients being treated with vancomycin and high-dose teicoplanin. Antimicrob. Agents Chemother. (1992) 36:1204–1207.
  • RYBAK MJ, ALBRECHT LM, BOIKE SC, CHANDRASEKARPH: Nephrotoxicity of vancomycin, alone and with an amin ogly co side. J. Antimicrob. Chemother. (1990) 25:679–687.
  • PESTOTNIK SL, CLASSEN DC, LLOYD JF, BURKE JP:Adverse effects of intravenous vancomycin in hospital patients: attributable costs and excess length of stay. Abstracts of the 35th Infectious Diseases Society of America Annual Meeting. San Francisco, USA (1997) Abstract 376.
  • MARKOWITZ N, QUINN EL, SARAVOLATZ LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infections. Ann. Intern. Med. (1992)117:390–398.
  • HARDY D, AMSTERDAM D, MANDELL LA, ROTSTEIN C:Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin and other antimicrobial agents against bloodstream isolates of Gram-positive cocci. Antimicrob. Agents Chemother. (2000) 44:802–805.
  • HOOGKAMP-KORSTANJE JAA, ROELOFS-WILLEMSE J: Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates. J. Antimicrob. Chemother. (2000) 45:31–39.
  • DELGADO G, NEUHASER MM, BEARDEN DT, DANZIGER LH: Quinupristin-dalfopristin: an overview. Pharmaco-ther. (2000) 20:1469–1485.
  • ••A comprehensive review of quinupristin-dalfopristin.
  • RUBENSTEIN E, PROKOCIMER P, TALBOT GH: Safety andtolerability of quinupristin/dalfopristin: administra-tion guidelines. J. Antimicrob. Chemother. (1999) 44 (Suppl. A):37–46.
  • MANDLER HD, BLUMBERG EA, FUCHS AE, MOLAVI A, WOOD CA: Arthralgias and myalgias associated with quinupristin/dalfopristin (Synercid) treatment of infections caused by vancomycin-resistant Entero-coccus faecium (VREF). Abstracts of the 36th Infectious Diseases Society of America Annual Meeting. Denver, USA (1998) Abstract 608.
  • Yu VL, Merigan TC, Barriere SL (Eds.), Williams & Wilkins, Baltimore (1998):963–972.
  • IMS Health, Inc. database (2001).
  • SLEE AM, WUONOLA MA, MCRIPLEY RJ, et al.: Oxazolidi-nones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob. Agents Chemother. (1987) 31:1791–1797.
  • ••Original description of potential clinically relevantoxazolidinones.
  • BARRY A: In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents. Antimi-crob. Agents Chemother. (1988) 32:150–152.
  • BRUMFITT W, HAMILTON-MILLER JMT: In vitro microbiological activities of DuP 105 and DuP 721, novel synthetic oxazolidinones. J. Antimicrob. Chemother. (1988) 21:711–720.
  • DALY JS, ELIOPOULOS GM, REISZNER E, MOELLERING RC: Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. J. Antimi-crob. Chemother. (1988) 21:721–730.
  • NEU HC, NOVELLI A, SAHA G, CHIN N-X: In vitro activi-ties of two oxazolidinone antimicrobial agents, DuP 105 and DuP 721. Antimicrob. Agents Chemother. (1988) 32:580–583.
  • ELIOPOULOS GM, WENNERSTEN CB, GOLD HS, MOELLERING RC: In vitro activities of new oxazolidi-none antimicrobial agents against enterococci. Antimi-crob. Agents Chemother. (1996) 40:1745–1747.
  • KAATZ GW, SEO SM: In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylo-coccus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chemother. (1996) 40:799–801.
  • MASON EO, LAMBERTH LB, KAPLAN SL: In vitro activi-ties of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. (1996) 40:1039–1040.
  • ZURENKO GE, YAGI BH, SHAADT RD, et al.: In vitro activities of U-100592 and U-100766, novel oxazolidi-none antibacterial agents. Antimicrob. Agents Chemother. (1996) 40:839–845.
  • JORGENSEN JH, MCELMEEL ML, TRIPPY CW: In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species. Antimi-crob. Agents Chemother. (1997) 41 :465–467.
  • DRESSER LD, RYBAK MJ: The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy (1998) 18:456–462.
  • •A review of eperezolid and linezolid.
  • RYBAK MJ, CAPPELLETTY DM, MOLDOVAN T, AESCHLIMANN JR, KAATZ GW: Comparative in vitro activities and postantibiotic effects of the oxazolidi-none compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus van co my cin against Staphylococcus aureus, coagulase-negative staphylo-cocci, Enterococcus faecalis and Enterococcus faecium. Antimicrob. Agents Chemother. (1998) 42:721–724.
  • NOSKIN GA, SIDDIQUI F, STOSOR V, HACEK D, PETERSON LR: In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimi-crob. Agents Chemother. (1999) 43:2059–2062.
  • VON EIFF C, PETERS G: Comparative in vitro activities of moxifloxacin, trovafloxacin, quinupristin / dalfopristin and linezolid against staphylococci. J. Antimicrob. Chemother. (1999) 43:569–573.
  • JOHNSON AP, WARNER M, LIVERMORE DM: Activity of linezolid against multi-resistant Gram-positive bacteria from diverse hospitals in the United Kingdom. J. Antimicrob. Chemother. (2000) 45:225–230.
  • HENWOOD CJ, LIVERMORE DM, JOHNSON AP, et al: Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. Antimicrob. Chemother. (2000) 46:931–940.
  • ASHTEKAR DR, COSTA-PERIERA R, SHRINIVASAN T, IYYER R, VISHVANATHAN N, RITTEL W: Oxazolidinones, anew class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP 721. Diagn. Microbiol. Infect. Dis. (1991) 14:465–471.
  • CYNAMON MH, KLEMENS SP, SHARPE CA, CHASE S: Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. (1999) 43:1189–1191.
  • CLEMETT D, MARKHAM A: Linezolid. Drugs (2000) 59:815–827.
  • ••A thorough review of linezolid.
  • EUSTICE DC, FELDMAN PA, ZAJAC I, SLEE AM: Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis. Antimi-crob. Agents Chemother. (1988) 32:1218–1222.
  • UN AH, MURRAY RW, VIDMAR TJ, MAROTTI KR: The oxazolidinone eperezolid binds to the 505 ribosomal subunit and competes with binding of chloram-phenicol and lincomycin. Antimicrob. Agents Chemother. (1997) 41:2127–2131.
  • SWANEY SM, AOKI H, GANOZA MC, SHINABARGER DL:The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother. (1998) 42:3251–3255.
  • MATASSOVA NB, RODNINA MV, ENDERMANN R, et al:Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA (1999) 5:939–946.
  • SHINABARGER DL: Mechanism of action of the oxazolidinone antibacterial agents. Exp. Opin. Invest. Drugs (1999) 8:1195–1202.
  • ZURENKO GE, TODD WM, HAFKIN B, et al.:Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid. Program and Abstracts of the 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999) Abstract 848.
  • ZURENKO GE: linezolid and beyond. Program and Abstracts of the 40th Intel-science Conference on Antimicro-bial Agents and Chemotherapy. Toronto, Ontario, Canada (2000) Abstract 637.
  • BRICKNER SJ, HUTCHINSON DK, BARBACHYN MR, et al.:Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections. J. Med. Chem. (1996) 39:673–679.
  • Lorian V (Ed.), Williams & Wilkins, Baltimore, USA (1990:432–492.
  • FORD CW, HAMEL JC, WILSON DM, et al.: In vivo activitiesof U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob. Agents Chemother. (1996) 40:1508–1513.
  • MULAZIMOGLU L, DRENNING SD, YU VL: In vitro activi-ties of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin) and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chemother. (1996) 40:2428–2430.
  • BRUSS JB, SMITH LG, DUVALL SE, et al.: Safety andtolerance of linezolid: adverse events reported in Phase III trials. Program and Abstracts of the 40th Intel-sci-ence Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada (2000) Abstract 2236.
  • MARTIN JP, HERBERG JG, SLATTER JG, DUPUIS MJ:Although a novel microtiter-plate assay demonstrates that linezolid (PNU-100766) is a weak, competitive (reversible) monoamine oxidase inhibitor (MAO A), no clinical evidence of MAO A inhibition in clinical trials has been observed. Program and Abstracts of the 38th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998) Abstract A–85.
  • WALKER SE, SHULMAN KI, TAILOR SA, GARDNER D: Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. J. Clin. Psychophar-macol. (1996) 16:383–388.
  • KLOSS P, XIONG L, SHINABARGER DL, MANKIN AS: Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol. Biol. (1999) 294:93–101.
  • •Reveals the probable site of binding and action of linezolid employing Halobacterium halobium, an archaeon possessing a single copy of the rRNA operon.
  • XIONG L, KLOSS P, DOUTHWAITE S, et al.: Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J Bacteriol (2000) 182:5325–5331.
  • ••Establishes the site of action of linezolid and describesadditional mutations conferring linezolid resistance.
  • Hill WE, Dahlberg A, Garrett RA, Moore PR, Schlessinger D, Warner JR (Eds.), American Society for Microbiology, Washington, DC, USA (1990):168–179.
  • FERNANDEZ-MUNOZ R, MONRO RE, TORRES-PINEDO R, VAZQUEZ D: Substrate- and antibiotic-binding sites at the peptidyl-transferase center of Escherichia coli ribosomes. Studies on the chloramphenicol, lincomycin and erythromycin sites. Eur. j Biochem. (1971) 23:185–193.
  • JONES RN, BARRETT MS, ERWIN ME: In vitro activity and spectrum of LY333328, a novel glycopeptide deriva-tive. Antimicrob. Agents Chemother. (1996) 41:488–493.
  • SCHWALBE RS, MCINTOSH AC, QAIYUMI S, et al.: In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob. Agents Chemother. (1996) 40:2416–2419.
  • SUM PE, SUM PW, PROJAN SJ: Recent developments in tetracycline antibiotics. Curr. Pharm. Res. (1998) 4:119–132.
  • PETERSEN PJ, JACOBUS NV, WEISS WJ, SUM PE, TESTA RT: In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of min o cyclin e (GAR-936). Antimicrob. Agents Chemother. (1999) 43:738–744.
  • GALES AC, JONES RN: Antimicrobial activity and spectrum of the new glycylcycline GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn. Microbiol. Infect. Dis. (2000) 36:19–36.
  • PROJAN SJ: Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmaco-therapy (2000) 20:219S–223S.
  • TALLY FP, DEBRUIN MF: Development of dap tomycin for Gram-positive infections. J Antimicrob. Chemother. (2000) 46:523–526.
  • SNYDMAN DR, JACOBUS NV, MCDERMOTT LA, LONKS JR, BOYCE JM: Comparative in vitro activities of daptomycin and vancomycin against resistant Gram-positive pathogens. Antimicrob. Agents Chemother. (2000) 44:3447–3450.
  • MALATHUM K, COQUE TM, SINGH KV, MURRAY BE: In vitro activities of two ketolides, MIR 3647 and HMR 3004, against Gram-positive bacteria. Antimicrob. Agents Chemother. (1999) 43:930–936.
  • ANDREWS JM, WELLER TMA, ASHBY JP, WALKER RM, WISE R: The in vitro activity of ABT773, a new ketolide antimicrobial agent. J. Antimicrob. Chemother. (2000) 46:1017–1022.
  • JONES RN, HARE RS, SABATELLI FJ: In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial. Antimicrob. Chemother. (2001) 47:15–25.
  • AARESTRUP FM: Association between decreased susceptibility to a new antibiotic for treatment of human diseases, everninomicin (SCH 27899) and resistance to an antibiotic used for growth promotion in animals, avilamycin. Microb. Drug Resist. (1998) 4:137–141.
  • GENIN MJ, ALLWINE DA, ANDERSON DJ, et al.: Substituent effects on the antibacterial activity of nitrogen-carbon linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious Gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis. J. Med. Chem. (2000) 43:953–970.
  • COTTAGNOUD P, GERBER CM, ACOSTA F, COTTAG-NOUD M, NEFTEL K, TAUBER MG: linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model. J. Antimicrob. Chemother. (2000) 46:981–985.

Websites

  • www.fda.gov/cder/foi/labe1/2000/21130161.pdf US Food and Drug Administration approved labelling for linezolid.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.